<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149543">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01744288</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C00079</org_study_id>
    <nct_id>NCT01744288</nct_id>
  </id_info>
  <brief_title>Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets</brief_title>
  <official_title>A Open Label, Randomized, Crossover and Potential Parallel, Single Dose Study of Ticagrelor 180 mg and Acetylsalicylic Acid (ASA) in Healthy Volunteers Followed by Autologous in Vivo Platelet Transfusion to Determine the Effects of Platelet Supplementation on the Reversibility of Platelet Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to see if platelet transfusion stop or lessen the effect of the drug on platelets
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A open label, randomized, crossover and potential parallel, single dose study of ticagrelor
      180 mg and acetylsalicylic acid (ASA) in healthy volunteers followed by autologous in vivo
      platelet transfusion to determine the effects of platelet supplementation on the
      reversibility of platelet inhibition
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacodynamics in terms of percent of inhibition of adenosine phosphatase (ADP)-induced platelet aggregation assessed by light transmission aggregometry (LTA) after loading dose of Ticagrelor</measure>
    <time_frame>Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics in  terms of platelet reactivity as measured by P2Y12 Reaction Units (PRU) using VerifyNow™ after loading dose of Ticagrelor</measure>
    <time_frame>Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics in  terms of platelet reactivity as measured by P2Y12 Reaction Units (PRU) using VerifyNow™ after loading dose of  Clopidogrel</measure>
    <time_frame>Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics in terms of percent of inhibition of adenosine phosphatase (ADP)-induced platelet aggregation assessed by light transmission aggregometry (LTA) after loading dose of Clopidogrel</measure>
    <time_frame>Predose, 0h, 2h,6h,12h,24h,36h,48h,60h,72h,84h and 96h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile in terms of adverse events, blood pressure, pulse, temperature, ECG (Electrocardiogram),  physical examination, and safety laboratory variables</measure>
    <time_frame>up to 9 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Inhibition on Platelet Aggregation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor with Platelet transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor without Platelet transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel with Platelet transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel without Platelet transfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Oral single loading dose 180ng</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Oral single loading dose 600mg</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>81mg once daily from day -2 up to platelet transfusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Healthy male and/or female volunteers aged 18 to 50 years, inclusive, with suitable
             veins for cannulation or repeated venipuncture. (Healthy as determined by medical
             history and physical examination, laboratory parameters, electrocardiogram (ECG)
             perform

          -  Have a body mass index (BMI) between 18 and 35 kg/m2 (inclusive) and weigh at least
             50 kg and no more than 120 kg

        Exclusion Criteria:

          -  ADP induced platelet aggregation &lt;60% prior to platelet apheresis

          -  History of peptic ulcer disease  Healthy volunteers with a propensity to bleed (eg,
             due to recent trauma, recent surgery, active or recent gastrointestinal bleeding or
             moderate hepatic impairment)

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of the investigational product

          -  Current smokers, those who have smoked or used nicotine products within the previous
             3 months and those who tested positive for cotinine at screening or at admission to
             the study center
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Carlson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Wilmington US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phil Leese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Overland Park US, Quintiles, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judi Hsia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wilmington, US AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>December 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1 Safety ,</keyword>
  <keyword>pharmacodynamic,</keyword>
  <keyword>Ticagrelor,</keyword>
  <keyword>Clopidogrel,</keyword>
  <keyword>Platelets</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
